Please join the B. Riley Healthcare Equity Research team during their two-day Neuro & Ophthalmology Investor Conference featuring 30+ SMiD cap public and private biotech companies focused on the development and commercialization of innovative treatment, testing, and delivery modalities, all driving toward a common aspiration of aiding afflicted patients with a broad array of neurodegenerative, neuropsychiatry and ophthalmology disorders, including but not limited to:
- Proteinopathies ranging from monogenic lysosomal storage disorders, e.g., MPS 1-IV, Gaucher’s, to complex dementias, e.g., DLB, FTD;
- Inflammatory and Immunomodulatory diseases, e.g., ALS, GA/dry AMD, MS; and
- Mental Health disease states of high public policy interest, e.g., Alzheimer’s, Depression/Suicidality.
Additionally, the conference will feature multiple expert panel discussions aimed at reviewing current dynamics across multiple CNS and eye disorders as it pertains to regulatory landscape, impact of COVID, and emergence of novel, more targeted therapeutic modalities, e.g., cell/gene therapy, allosteric modulators/protein degradation, intranasal, approaching additional clinical data validation.
If you have questions or need assistance, please contact the Issuer Direct Help Desk or call them at (919) 228-6250.
